\nTeleflex Incorporated (NYSE: TFX) (the \u201cCompany\u201d) today announced financial results for the first quarter ended March 31, 2026.<\/p>\n
First<\/i> quarter 2026 continuing operations financial summary<\/i><\/b>1<\/sup><\/i><\/p>\n 2026 continuing operations guidance summary<\/i><\/b>1<\/sup><\/i><\/p>\n \n“Our first-quarter performance reflects disciplined execution and meaningful progress against our transformation plan,” said Stuart Randle, Teleflex’s Interim President and Chief Executive Officer. “We delivered a strong start to the year, with 5.1% pro forma adjusted constant currency revenue growth year-over-year, and we continue to expect our two strategic divestitures to close in the second half of 2026. We remain committed to using the majority of the net proceeds from the sales transactions to return capital to shareholders through our $1 billion share repurchase authorization, while also reducing debt by $800 million to enhance financial flexibility and support future growth. These actions are advancing our strategy to optimize our portfolio, strengthen Teleflex’s position as a focused medical technologies leader and drive long-term value creation.”<\/p>\n \nMr. Randle continued, \u201cWe recently announced the appointment of Jason Weidman as President and Chief Executive Officer, effective June 8, 2026. His deep medical technology expertise and proven track record of driving growth and innovation make him well suited to lead Teleflex into its next chapter and capitalize on the opportunities ahead. Additionally, consistent with our commitment to strong governance and creating shareholder value, we announced several actions in April, including the nomination of Michael J. Tokich to our Board of Directors, the initiation of opportunistic open-market share repurchases in the second quarter and our intent to establish a new Growth and Operating Committee of the Board.\u201d<\/p>\n (1) Continuing operations excludes the Acute Care, Interventional Urology, and OEM businesses that were classified as discontinued operations during the fourth quarter of 2025 as a result of our entry into agreements to divest those businesses, which we refer to as the \u201cStrategic Divestitures”.<\/i><\/p>\n (2) Pro forma adjusted constant currency revenue growth includes revenue generated by the acquired Vascular Intervention business in the prior year period, and excludes (a) revenue generated by products previously included within continuing operations that were discontinued at the end of 2025 due to a strategic realignment and (b) the impact of foreign exchange.<\/i><\/p>\n NET REVENUE BY GLOBAL PRODUCT CATEGORY<\/b><\/p>\n \nThe following table provides information regarding net revenues in each of the Company’s global product categories for the three months ended March 31, 2026 and the comparable prior year period on both a GAAP and pro forma adjusted constant currency basis.<\/p>\n \n\u00a0<\/p>\n<\/td>\n Three Months Ended<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \n\u00a0<\/p>\n<\/td>\n March 31, 2026<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n March 30, 2025<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n % Increase<\/b><\/p>\n<\/td>\n \/<\/b><\/p>\n<\/td>\n (Decrease)<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \n\u00a0<\/p>\n<\/td>\n Reported<\/b><\/p>\n revenue<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n Adjustment<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n Pro Forma<\/b><\/p>\n Adjusted<\/b><\/p>\n Revenue<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n Reported<\/b><\/p>\n revenue<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n Adjustment<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n Pro Forma<\/b><\/p>\n Adjusted<\/b><\/p>\n Revenue<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n Reported<\/b><\/p>\n Revenue<\/b><\/p>\n Growth<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n Currency<\/b><\/p>\n Impact<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n Adjustment<\/b><\/p>\n impact<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n Pro Forma<\/b><\/p>\n Adjusted<\/b><\/p>\n Constant<\/b><\/p>\n Currency<\/b><\/p>\n Revenue<\/b><\/p>\n Growth<\/b><\/p>\n<\/td>\n<\/tr>\n \nVascular Access<\/p>\n<\/td>\n \n$236.8<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n$\u2014<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n$236.8<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n$219.1<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n$\u2014<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n$219.1<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n8.1%<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n3.3%<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u2014%<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n4.8%<\/p>\n<\/td>\n<\/tr>\n \nInterventional1<\/sup><\/p>\n<\/td>\n \n204.7<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u2014<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n204.7<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n100.2<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n92.6<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n192.8<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n104.4%<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n3.1%<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n98.3%<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n3.0%<\/p>\n<\/td>\n<\/tr>\n \nSurgical2<\/sup><\/p>\n<\/td>\n \n106.8<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u2014<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n106.8<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n95.0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n(0.5)<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n94.5<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n12.4%<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n3.1%<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n(0.6)%<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n9.9%<\/p>\n<\/td>\n<\/tr>\n \nConsolidated1<\/sup><\/p>\n<\/td>\n \n$548.3<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n$\u2014<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n$548.3<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n$414.3<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n$92.1<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n$506.4<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n32.3%<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n3.2%<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n24.0%<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n5.1%<\/p>\n<\/td>\n<\/tr>\n<\/table>\n \nNotes:<\/p>\n<\/td>\n \n(1) Adjustments are inclusive of Vascular Intervention pro forma and discontinued product adjustments.<\/p>\n<\/td>\n<\/tr>\n \n(2) Adjustments are inclusive of discontinued product adjustments<\/p>\n<\/td>\n<\/tr>\n \nSee Pro Forma Adjusted Revenue by Global Product Category table for reconciliation of adjustments.<\/p>\n<\/td>\n<\/tr>\n<\/table>\n OTHER CONTINUING OPERATIONS FINANCIAL HIGHLIGHTS<\/b><\/p>\n 2026 CONTINUING OPERATIONS OUTLOOK<\/b><\/p>\n \nOn a GAAP basis, the Company continues to expect full year 2026 revenue growth from continuing operations of 14.40% to 15.40%, including our estimate of an approximately 0.70% positive impact of foreign exchange rate fluctuations. On a pro forma adjusted constant currency basis, the Company is maintaining full year 2026 revenue growth from continuing operations of 4.50% to 5.50%.<\/p>\n \nThe Company maintained its full year 2026 GAAP diluted earnings per share from continuing operations outlook range of $2.90 to $3.20. The Company continues to expect full year 2026 adjusted diluted earnings per share from continuing operations of $6.25 to $6.55.<\/p>\n Forecasted 2026 Pro Forma Adjusted Revenue From Continuing Operations Reconciliation<\/i><\/b><\/p>\n \n\u00a0<\/p>\n<\/td>\n 2025<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n 2026 Guidance<\/b><\/p>\n<\/td>\n<\/tr>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n Low<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n High<\/b><\/p>\n<\/td>\n<\/tr>\n \nGAAP revenue<\/p>\n<\/td>\n \n$1,992.7<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n$2,280<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n$2,300<\/p>\n<\/td>\n<\/tr>\n \nVascular Intervention pro forma adjustment<\/p>\n<\/td>\n \n$199.0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u2014<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u2014<\/p>\n<\/td>\n<\/tr>\n \nDiscontinued product adjustment<\/p>\n<\/td>\n \n$(14.3)<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u2014<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u2014<\/p>\n<\/td>\n<\/tr>\n \nItalian payback measure adjustment<\/p>\n<\/td>\n \n$(9.0)<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u2014<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u2014<\/p>\n<\/td>\n<\/tr>\n \nPro forma adjusted revenue<\/p>\n<\/td>\n \n$2,168.4<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n$2,280<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n$2,300<\/p>\n<\/td>\n<\/tr>\n<\/table>\n Forecasted<\/i> 2026 Pro Forma Adjusted Constant Currency Revenue Percent Growth From Continuing Operations Reconciliation<\/i><\/b><\/p>\n \n\u00a0<\/p>\n<\/td>\n Low<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n High<\/b><\/p>\n<\/td>\n<\/tr>\n \nForecasted 2026 GAAP revenue growth<\/p>\n<\/td>\n \n14.4%<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n15.4%<\/p>\n<\/td>\n<\/tr>\n \nVascular Intervention pro forma adjustment<\/p>\n<\/td>\n \n10.0%<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n10.0%<\/p>\n<\/td>\n<\/tr>\n \nDiscontinued product adjustment<\/p>\n<\/td>\n \n(0.7)%<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n(0.7)%<\/p>\n<\/td>\n<\/tr>\n \nItalian payback measure adjustment<\/p>\n<\/td>\n \n(0.5)%<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n(0.5)%<\/p>\n<\/td>\n<\/tr>\n \nBase year adjustment (GAAP versus pro forma adjusted)<\/p>\n<\/td>\n \n0.4%<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n0.4%<\/p>\n<\/td>\n<\/tr>\n \nEstimated impact of foreign currency exchange rate fluctuations<\/p>\n<\/td>\n \n0.7%<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n0.7%<\/p>\n<\/td>\n<\/tr>\n \nForecasted 2026 pro forma adjusted constant currency revenue growth<\/p>\n<\/td>\n \n4.5%<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n5.5%<\/p>\n<\/td>\n<\/tr>\n<\/table>\n Forecasted 2026 Adjusted Diluted Earnings Per Share From Continuing Operations Reconciliation<\/i><\/b><\/p>\n \n\u00a0<\/p>\n<\/td>\n Low<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n High<\/b><\/p>\n<\/td>\n<\/tr>\n \nForecasted GAAP diluted earnings per share from continuing operations<\/p>\n<\/td>\n \n$2.90<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n$3.20<\/p>\n<\/td>\n<\/tr>\n \nRestructuring and optimization items, net of tax<\/p>\n<\/td>\n \n$0.90<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n$0.90<\/p>\n<\/td>\n<\/tr>\n \nAcquisition, integration and divestiture related items, net of tax<\/p>\n<\/td>\n \n$0.61<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n$0.61<\/p>\n<\/td>\n<\/tr>\n \nOther items, net of tax<\/p>\n<\/td>\n \n$(0.65)<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n$(0.65)<\/p>\n<\/td>\n<\/tr>\n \nERP implementation, net of tax<\/p>\n<\/td>\n \n$0.30<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n$0.30<\/p>\n<\/td>\n<\/tr>\n \nMDR, net of tax<\/p>\n<\/td>\n \n$0.02<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n$0.02<\/p>\n<\/td>\n<\/tr>\n \nIntangible amortization expense, net of tax<\/p>\n<\/td>\n \n$2.17<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n$2.17<\/p>\n<\/td>\n<\/tr>\n \nForecasted adjusted diluted earnings per share from continuing operations, net of tax<\/p>\n<\/td>\n \n$6.25<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n$6.55<\/p>\n<\/td>\n<\/tr>\n<\/table>\n CONFERENCE CALL WEBCAST AND ADDITIONAL INFORMATION<\/b><\/p>\n \n\u00a0<\/p>\n<\/td>\n Q1 2026<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n Q1 2025<\/b><\/p>\n<\/td>\n<\/tr>\n \nVascular<\/p>\n<\/td>\n \n236.8<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n219.1<\/p>\n<\/td>\n<\/tr>\n \nInterventional<\/p>\n<\/td>\n \n204.7<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n100.2<\/p>\n<\/td>\n<\/tr>\n \nSurgical<\/p>\n<\/td>\n \n106.8<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n95.0<\/p>\n<\/td>\n<\/tr>\n \nGAAP revenue<\/p>\n<\/td>\n \n548.3<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n414.3<\/p>\n<\/td>\n<\/tr>\n \nInterventional – Vascular Intervention<\/p>\n<\/td>\n \n\u2014<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n95.2<\/p>\n<\/td>\n<\/tr>\n \nInterventional – Discontinued Products<\/p>\n<\/td>\n \n\u2014<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n(2.6)<\/p>\n<\/td>\n<\/tr>\n \nSurgical – Discontinued Products<\/p>\n<\/td>\n \n\u2014<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n(0.5)<\/p>\n<\/td>\n<\/tr>\n \nPro forma adjusted revenue<\/p>\n<\/td>\n \n$548.3<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n$506.4<\/p>\n<\/td>\n<\/tr>\n \nVascular<\/p>\n<\/td>\n \n236.8<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n219.1<\/p>\n<\/td>\n<\/tr>\n \nInterventional<\/p>\n<\/td>\n \n204.7<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n192.8<\/p>\n<\/td>\n<\/tr>\n \nSurgical<\/p>\n<\/td>\n \n106.8<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n94.5<\/p>\n<\/td>\n<\/tr>\n<\/table>\n Reconciliation of Consolidated Statement of Income Items (Dollars in millions, except per share data)<\/b><\/p>\n Three Months Ended March 31, 2026<\/b><\/p>\n<\/td>\n<\/tr>\n \n\u00a0<\/p>\n<\/td>\n Revenue<\/b><\/p>\n<\/td>\n Gross<\/b><\/p>\n margin<\/b><\/p>\n<\/td>\n SG&A (1)<\/b><\/p>\n<\/td>\n R&D (1)<\/b><\/p>\n<\/td>\n Operating<\/b><\/p>\n margin (2)<\/b><\/p>\n<\/td>\n (Loss) Income<\/b><\/p>\n before income<\/b><\/p>\n taxes<\/b><\/p>\n<\/td>\n Income tax<\/b><\/p>\n expense<\/b><\/p>\n<\/td>\n Effective<\/b><\/p>\n income tax<\/b><\/p>\n rate<\/b><\/p>\n<\/td>\n Diluted (loss)<\/b><\/p>\n earnings per<\/b><\/p>\n share from<\/b><\/p>\n continuing<\/b><\/p>\n operations<\/b><\/p>\n<\/td>\n<\/tr>\n \nGAAP Basis – Continuing Operations<\/p>\n<\/td>\n \n$548.3<\/p>\n<\/td>\n \n56.1%<\/p>\n<\/td>\n \n41.2%<\/p>\n<\/td>\n \n8.1%<\/p>\n<\/td>\n \n3.7%<\/p>\n<\/td>\n \n$(3.8)<\/p>\n<\/td>\n \n$1.0<\/p>\n<\/td>\n \n(26.4)%<\/p>\n<\/td>\n \n$(0.11)<\/p>\n<\/td>\n<\/tr>\n Adjustments<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nRestructuring and optimization charges (A)<\/p>\n<\/td>\n \n\u2014<\/p>\n<\/td>\n \n0.6<\/p>\n<\/td>\n \n(1.4)<\/p>\n<\/td>\n \n\u2014<\/p>\n<\/td>\n \n5.0<\/p>\n<\/td>\n \n28.0<\/p>\n<\/td>\n \n4.4<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n0.54<\/p>\n<\/td>\n<\/tr>\n \nAcquisition, integration and divestiture related items (B)<\/p>\n<\/td>\n \n\u2014<\/p>\n<\/td>\n \n1.4<\/p>\n<\/td>\n \n(1.0)<\/p>\n<\/td>\n \n\u2014<\/p>\n<\/td>\n \n2.4<\/p>\n<\/td>\n \n13.0<\/p>\n<\/td>\n \n3.1<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n0.22<\/p>\n<\/td>\n<\/tr>\n \nERP implementation<\/p>\n<\/td>\n \n\u2014<\/p>\n<\/td>\n \n\u2014<\/p>\n<\/td>\n \n(0.7)<\/p>\n<\/td>\n \n\u2014<\/p>\n<\/td>\n \n0.7<\/p>\n<\/td>\n \n3.9<\/p>\n<\/td>\n \n0.7<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n0.07<\/p>\n<\/td>\n<\/tr>\n \nMDR<\/p>\n<\/td>\n \n\u2014<\/p>\n<\/td>\n \n\u2014<\/p>\n<\/td>\n \n\u2014<\/p>\n<\/td>\n \n(0.1)<\/p>\n<\/td>\n \n0.1<\/p>\n<\/td>\n \n0.4<\/p>\n<\/td>\n \n\u2014<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n0.01<\/p>\n<\/td>\n<\/tr>\n \nIntangible amortization expense<\/p>\n<\/td>\n \n\u2014<\/p>\n<\/td>\n \n3.3<\/p>\n<\/td>\n \n(2.9)<\/p>\n<\/td>\n \n\u2014<\/p>\n<\/td>\n \n6.2<\/p>\n<\/td>\n \n33.9<\/p>\n<\/td>\n \n4.6<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n0.66<\/p>\n<\/td>\n<\/tr>\n \nAdjustments total<\/p>\n<\/td>\n \n\u2014<\/p>\n<\/td>\n \n5.3<\/p>\n<\/td>\n \n(6.0)<\/p>\n<\/td>\n \n(0.1)<\/p>\n<\/td>\n \n14.4<\/p>\n<\/td>\n \n79.2<\/p>\n<\/td>\n \n12.8<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n1.50<\/p>\n<\/td>\n<\/tr>\n Adjusted basis<\/b><\/p>\n<\/td>\n $548.3<\/b><\/p>\n<\/td>\n 61.4%<\/b><\/p>\n<\/td>\n 35.2%<\/b><\/p>\n<\/td>\n 8.0%<\/b><\/p>\n<\/td>\n 18.1%<\/b><\/p>\n<\/td>\n $75.4<\/b><\/p>\n<\/td>\n $13.8<\/b><\/p>\n<\/td>\n 18.3%<\/b><\/p>\n<\/td>\n $1.39<\/b><\/p>\n<\/td>\n<\/tr>\n<\/table>\n Three Months Ended March 30, 2025<\/b><\/p>\n<\/td>\n<\/tr>\n \n\u00a0<\/p>\n<\/td>\n Revenue<\/b><\/p>\n<\/td>\n Gross<\/b><\/p>\n margin<\/b><\/p>\n<\/td>\n SG&A (1)<\/b><\/p>\n<\/td>\n R&D (1)<\/b><\/p>\n<\/td>\n Operating<\/b><\/p>\n margin (2)<\/b><\/p>\n<\/td>\n Income before<\/b><\/p>\n income taxes<\/b><\/p>\n<\/td>\n Income tax<\/b><\/p>\n expense<\/b><\/p>\n<\/td>\n Effective<\/b><\/p>\n income tax<\/b><\/p>\n rate<\/b><\/p>\n<\/td>\n Diluted<\/b><\/p>\n earnings per<\/b><\/p>\n share from<\/b><\/p>\n continuing<\/b><\/p>\n operations<\/b><\/p>\n<\/td>\n<\/tr>\n \nGAAP Basis – Continuing Operations<\/p>\n<\/td>\n \n$414.3<\/p>\n<\/td>\n \n61.7%<\/p>\n<\/td>\n \n36.9%<\/p>\n<\/td>\n \n6.1%<\/p>\n<\/td>\n \n18.3%<\/p>\n<\/td>\n \n$58.8<\/p>\n<\/td>\n \n$6.4<\/p>\n<\/td>\n \n10.9%<\/p>\n<\/td>\n \n$1.14<\/p>\n<\/td>\n<\/tr>\n Adjustments<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nRestructuring and optimization charges (A)<\/p>\n<\/td>\n \n\u2014<\/p>\n<\/td>\n \n1.1<\/p>\n<\/td>\n \n\u2014<\/p>\n<\/td>\n \n\u2014<\/p>\n<\/td>\n \n1.5<\/p>\n<\/td>\n \n6.0<\/p>\n<\/td>\n \n1.0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n0.11<\/p>\n<\/td>\n<\/tr>\n \nAcquisition, integration and divestiture related items (B)<\/p>\n<\/td>\n \n\u2014<\/p>\n<\/td>\n \n\u2014<\/p>\n<\/td>\n \n4.4<\/p>\n<\/td>\n \n\u2014<\/p>\n<\/td>\n \n(4.4)<\/p>\n<\/td>\n \n(18.1)<\/p>\n<\/td>\n \n0.8<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n(0.42)<\/p>\n<\/td>\n<\/tr>\n \nERP implementation<\/p>\n<\/td>\n \n\u2014<\/p>\n<\/td>\n \n\u2014<\/p>\n<\/td>\n \n(1.4)<\/p>\n<\/td>\n \n\u2014<\/p>\n<\/td>\n \n1.4<\/p>\n<\/td>\n \n5.9<\/p>\n<\/td>\n \n1.0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n0.11<\/p>\n<\/td>\n<\/tr>\n \nMDR<\/p>\n<\/td>\n \n\u2014<\/p>\n<\/td>\n \n\u2014<\/p>\n<\/td>\n \n\u2014<\/p>\n<\/td>\n \n(0.2)<\/p>\n<\/td>\n \n0.2<\/p>\n<\/td>\n \n0.7<\/p>\n<\/td>\n \n\u2014<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n0.02<\/p>\n<\/td>\n<\/tr>\n \nIntangible amortization expense<\/p>\n<\/td>\n \n\u2014<\/p>\n<\/td>\n \n3.3<\/p>\n<\/td>\n \n(2.9)<\/p>\n<\/td>\n \n\u2014<\/p>\n<\/td>\n \n6.2<\/p>\n<\/td>\n \n25.6<\/p>\n<\/td>\n \n3.1<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n0.49<\/p>\n<\/td>\n<\/tr>\n \nTax adjustments<\/p>\n<\/td>\n \n\u2014<\/p>\n<\/td>\n \n\u2014<\/p>\n<\/td>\n \n\u2014<\/p>\n<\/td>\n \n\u2014<\/p>\n<\/td>\n \n\u2014<\/p>\n<\/td>\n \n\u2014<\/p>\n<\/td>\n \n0.7<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n(0.01)<\/p>\n<\/td>\n<\/tr>\n \nAdjustments total<\/p>\n<\/td>\n \n\u2014<\/p>\n<\/td>\n \n4.4<\/p>\n<\/td>\n \n0.1<\/p>\n<\/td>\n \n(0.2)<\/p>\n<\/td>\n \n4.9<\/p>\n<\/td>\n \n20.1<\/p>\n<\/td>\n \n6.6<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n0.30<\/p>\n<\/td>\n<\/tr>\n Adjusted basis<\/b><\/p>\n<\/td>\n $414.3<\/b><\/p>\n<\/td>\n 66.1%<\/b><\/p>\n<\/td>\n 37.0%<\/b><\/p>\n<\/td>\n 5.9%<\/b><\/p>\n<\/td>\n 23.2%<\/b><\/p>\n<\/td>\n $78.9<\/b><\/p>\n<\/td>\n $13.0<\/b><\/p>\n<\/td>\n 16.4%<\/b><\/p>\n<\/td>\n $1.44<\/b><\/p>\n<\/td>\n<\/tr>\n<\/table>\n \nNotes:<\/p>\n<\/td>\n \n(1) Selling, general and administrative expenses and research and development expenses are shown as a percentage of as reported and adjusted revenues.<\/p>\n<\/td>\n<\/tr>\n \n(2) Operating margin defined as Income from continuing operations before interest and taxes as a percentage of as reported and adjusted revenues.<\/p>\n<\/td>\n<\/tr>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nTotals may not sum due to rounding.<\/p>\n<\/td>\n<\/tr>\n<\/table>\n Tickmarks to Reconciliation Tables<\/b><\/p>\n (A)<\/i><\/b><\/p>\n<\/td>\n Restructuring and optimization charges \u2013 <\/b>For the three months ended March 31, 2026, pre-tax restructuring charges were $16.8 million and restructuring related charges were $11.3 million. For the three months ended March 30, 2025, pre-tax restructuring charges were $1.4 million and restructuring related charges were $4.6 million.<\/p>\n<\/td>\n<\/tr>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n (B)<\/i><\/b><\/p>\n<\/td>\n Acquisition, integration and divestiture related items \u2013 <\/b>For the three months ended March 31, 2026, these charges primarily related to the acquisition the Vascular Intervention business of BIOTRONIK SE & Co. KG, which is inclusive of inventory step-up costs of $7.8 million and acquisition and integration costs of $7.8 million, partially offset by a benefit from contingent consideration of $2.6 million. For the three months ended March 30, 2025, these charges primarily related to the pending acquisition of the Vascular Intervention business of BIOTRONIK SE & Co. KG, which is inclusive of $6.2 million of acquisition and integration costs offset by the recognition of a $22.5 million benefit related to non-designated foreign currency forward contracts.<\/p>\n<\/td>\n<\/tr>\n<\/table>\n ABOUT TELEFLEX INCORPORATED<\/b><\/p>\n \nAs a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people\u2019s lives. Through our vision to become the most trusted partner in healthcare, we offer a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology. We believe that the potential of great people, purpose driven innovation, and world-class products can shape the future direction of healthcare.<\/p>\n \nTeleflex is the home of Arrow\u2122, Barrigel\u2122, Deknatel\u2122, LMA\u2122, Pilling\u2122, QuikClot\u2122 R\u00fcsch\u2122, UroLift\u2122 and Weck\u2122 \u2013 trusted brands united by a common sense of purpose.<\/p>\n TELEFLEX INCORPORATED<\/b><\/p>\n CONSOLIDATED STATEMENTS OF INCOME (LOSS)<\/b><\/p>\n (Unaudited)<\/b><\/p>\n<\/td>\n<\/tr>\n \n\u00a0<\/p>\n<\/td>\n Three Months Ended<\/b><\/p>\n<\/td>\n<\/tr>\n \n\u00a0<\/p>\n<\/td>\n March 31, 2026<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n March 30, 2025<\/b><\/p>\n<\/td>\n<\/tr>\n \n\u00a0<\/p>\n<\/td>\n (Dollars and shares in thousands, except per share)<\/b><\/p>\n<\/td>\n<\/tr>\n \nNet revenues<\/p>\n<\/td>\n \n$<\/p>\n<\/td>\n \n548,262<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n$<\/p>\n<\/td>\n \n414,258<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nCost of goods sold<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n240,836<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n158,827<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nGross profit<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n307,426<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n255,431<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nSelling, general and administrative expenses<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n226,012<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n152,914<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nResearch and development expenses<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n44,386<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n25,295<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nRestructuring charges, separation costs and impairment charges<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n16,845<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n1,422<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nIncome from continuing operations before interest and taxes<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n20,183<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n75,800<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nInterest expense<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n25,718<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n18,537<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nInterest income<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n(1,708<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n(1,488<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n<\/tr>\n \n(Loss) income from continuing operations before taxes<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n(3,827<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n58,751<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nTaxes on income from continuing operations<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n1,011<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n6,417<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \n(Loss) income from continuing operations<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n(4,838<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n52,334<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nOperating (loss) income from discontinued operations<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n(2,643<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n50,060<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nTaxes on operating income from discontinued operations<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n673<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n7,392<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \n(Loss) income from discontinued operations<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n(3,316<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n42,668<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nNet (loss) income<\/p>\n<\/td>\n \n$<\/p>\n<\/td>\n \n(8,154<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n$<\/p>\n<\/td>\n \n95,002<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nEarnings per share:<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nBasic:<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \n(Loss) Income from continuing operations<\/p>\n<\/td>\n \n$<\/p>\n<\/td>\n \n(0.11<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n$<\/p>\n<\/td>\n \n1.14<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \n(Loss) Income from discontinued operations<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n(0.07<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n0.94<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nNet (loss) income<\/p>\n<\/td>\n \n$<\/p>\n<\/td>\n \n(0.18<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n$<\/p>\n<\/td>\n \n2.08<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nDiluted:<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \n(Loss) Income from continuing operations<\/p>\n<\/td>\n \n$<\/p>\n<\/td>\n \n(0.11<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n$<\/p>\n<\/td>\n \n1.14<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \n(Loss) Income from discontinued operations<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n(0.07<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n0.93<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nNet (loss) income<\/p>\n<\/td>\n \n$<\/p>\n<\/td>\n \n(0.18<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n$<\/p>\n<\/td>\n \n2.07<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nWeighted average common shares outstanding<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nBasic<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n44,257<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n45,782<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nDiluted<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n44,257<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n45,926<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n<\/table>\n TELEFLEX INCORPORATED<\/b><\/p>\n CONSOLIDATED BALANCE SHEETS<\/b><\/p>\n (Unaudited)<\/b><\/p>\n<\/td>\n<\/tr>\n \n\u00a0<\/p>\n<\/td>\n March 31, 2026<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n December 31, 2025<\/b><\/p>\n<\/td>\n<\/tr>\n \n\u00a0<\/p>\n<\/td>\n (Dollars in thousands)<\/b><\/p>\n<\/td>\n<\/tr>\n ASSETS<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nCurrent assets<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nCash and cash equivalents<\/p>\n<\/td>\n \n$<\/p>\n<\/td>\n \n309,411<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n$<\/p>\n<\/td>\n \n378,564<\/p>\n<\/td>\n<\/tr>\n \nAccounts receivable, net<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n365,526<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n345,583<\/p>\n<\/td>\n<\/tr>\n \nInventories<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n380,861<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n404,395<\/p>\n<\/td>\n<\/tr>\n \nPrepaid expenses and other current assets<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n149,808<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n150,678<\/p>\n<\/td>\n<\/tr>\n \nPrepaid taxes<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n16,793<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n19,566<\/p>\n<\/td>\n<\/tr>\n \nCurrent assets of discontinued operations<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n637,271<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n639,552<\/p>\n<\/td>\n<\/tr>\n \nTotal current assets<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n1,859,670<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n1,938,338<\/p>\n<\/td>\n<\/tr>\n \nProperty, plant and equipment, net<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n476,955<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n498,281<\/p>\n<\/td>\n<\/tr>\n \nOperating lease assets<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n84,912<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n91,817<\/p>\n<\/td>\n<\/tr>\n \nGoodwill<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n2,297,447<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n2,305,050<\/p>\n<\/td>\n<\/tr>\n \nIntangibles assets, net<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n1,485,885<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n1,524,150<\/p>\n<\/td>\n<\/tr>\n \nDeferred tax assets<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n12,206<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n12,593<\/p>\n<\/td>\n<\/tr>\n \nOther assets<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n113,557<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n112,984<\/p>\n<\/td>\n<\/tr>\n \nNon-current assets of discontinued operations<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n452,370<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n464,026<\/p>\n<\/td>\n<\/tr>\n \nTotal assets<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n6,783,002<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n6,947,239<\/p>\n<\/td>\n<\/tr>\n LIABILITIES AND EQUITY<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nCurrent liabilities<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nCurrent borrowings<\/p>\n<\/td>\n \n$<\/p>\n<\/td>\n \n103,125<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n$<\/p>\n<\/td>\n \n100,000<\/p>\n<\/td>\n<\/tr>\n \nAccounts payable<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n143,627<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n130,201<\/p>\n<\/td>\n<\/tr>\n \nAccrued expenses<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n118,423<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n117,350<\/p>\n<\/td>\n<\/tr>\n \nPayroll and benefit-related liabilities<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n103,345<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n124,769<\/p>\n<\/td>\n<\/tr>\n \nAccrued interest<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n16,478<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n5,404<\/p>\n<\/td>\n<\/tr>\n \nIncome taxes payable<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n11,824<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n18,787<\/p>\n<\/td>\n<\/tr>\n \nOther current liabilities<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n103,929<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n137,195<\/p>\n<\/td>\n<\/tr>\n \nCurrent liabilities of discontinued operations<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n127,298<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n128,320<\/p>\n<\/td>\n<\/tr>\n \nTotal current liabilities<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n728,049<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n762,026<\/p>\n<\/td>\n<\/tr>\n \nLong-term borrowings<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n2,514,268<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n2,541,449<\/p>\n<\/td>\n<\/tr>\n \nDeferred tax liabilities<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n169,429<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n183,749<\/p>\n<\/td>\n<\/tr>\n \nNoncurrent liability for uncertain tax positions<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n3,831<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n3,536<\/p>\n<\/td>\n<\/tr>\n \nNoncurrent operating lease liabilities<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n68,320<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n84,210<\/p>\n<\/td>\n<\/tr>\n \nOther liabilities<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n162,507<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n194,532<\/p>\n<\/td>\n<\/tr>\n \nNon-current liabilities of discontinued operations<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n52,162<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n52,969<\/p>\n<\/td>\n<\/tr>\n \nTotal liabilities<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n3,698,566<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n3,822,471<\/p>\n<\/td>\n<\/tr>\n \nCommitments and contingencies<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nTotal shareholders’ equity<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n3,084,436<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n3,124,768<\/p>\n<\/td>\n<\/tr>\n \nTotal liabilities and shareholders’ equity<\/p>\n<\/td>\n \n$<\/p>\n<\/td>\n \n6,783,002<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n$<\/p>\n<\/td>\n \n6,947,239<\/p>\n<\/td>\n<\/tr>\n TELEFLEX INCORPORATED<\/b><\/p>\n CONSOLIDATED STATEMENTS OF CASH FLOWS<\/b><\/p>\n (Unaudited)<\/b><\/p>\n<\/td>\n<\/tr>\n \n\u00a0<\/p>\n<\/td>\n Three Months Ended<\/b><\/p>\n<\/td>\n<\/tr>\n \n\u00a0<\/p>\n<\/td>\n March 31, 2026<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n March 30, 2025<\/b><\/p>\n<\/td>\n<\/tr>\n \n\u00a0<\/p>\n<\/td>\n (Dollars in thousands)<\/b><\/p>\n<\/td>\n<\/tr>\n \nCash flows from operating activities of continuing operations:<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nNet (loss) income<\/p>\n<\/td>\n \n$<\/p>\n<\/td>\n \n(8,154<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n$<\/p>\n<\/td>\n \n95,002<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nAdjustments to reconcile net income to net cash provided by operating activities:<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \n(Income) loss from discontinued operations<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n3,316<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n(42,668<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n<\/tr>\n \nDepreciation expense<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n19,853<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n13,037<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nIntangible asset amortization expense<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n33,890<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n25,583<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nDeferred financing costs and debt discount amortization expense<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n1,481<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n851<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nChanges in contingent consideration<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n(2,632<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n(1,795<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n<\/tr>\n \nStock-based compensation<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n6,742<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n6,630<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nGain on non-designated foreign currency forward contracts<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u2014<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n(23,268<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n<\/tr>\n \nDeferred income taxes, net<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n(12,710<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n(108<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n<\/tr>\n \nInterest benefit on swaps designated as net investment hedges<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n(8,305<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n(4,239<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n<\/tr>\n \nOther<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n3,558<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n762<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nChanges in assets and liabilities, net of effects of acquisitions and disposals:<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nAccounts receivable<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n(25,005<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n(10,939<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n<\/tr>\n \nInventories<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n16,473<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n(3,474<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n<\/tr>\n \nPrepaid expenses and other assets<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n3,432<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n(12,724<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n<\/tr>\n \nAccounts payable, accrued expenses and other liabilities<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n8,197<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n(17,488<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n<\/tr>\n \nIncome taxes receivable and payable, net<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n6,526<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n2,562<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nNet cash provided by operating activities from continuing operations<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n46,662<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n27,724<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nCash flows from investing activities of continuing operations:<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nExpenditures for property, plant and equipment<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n(18,791<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n(24,132<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n<\/tr>\n \nPayments for businesses and intangibles acquired, net of cash acquired<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u2014<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n(90<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n<\/tr>\n \nInsurance settlement proceeds<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u2014<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n6,307<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nNet payments on swaps designated as net investment hedges<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n(53,494<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u2014<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nPurchase of investments<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n(2,500<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n(5,000<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n<\/tr>\n \nNet cash used in investing activities from continuing operations<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n(74,785<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n(22,915<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n<\/tr>\n \nCash flows from financing activities of continuing operations:<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nProceeds from new borrowings<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u2014<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n300,000<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nReduction in borrowings<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n(25,250<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n(49,125<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n<\/tr>\n \nRepurchase of common stock<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u2014<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n(300,000<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n<\/tr>\n \nNet (payments) proceeds from share based compensation plans and related tax impacts<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n(4,627<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n7,348<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nPayments for contingent consideration<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n(58<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n(56<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n<\/tr>\n \nDividends paid<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n(15,050<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n(15,191<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n<\/tr>\n \nDebt extinguishment, issuance and amendment fees<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u2014<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n(2,500<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n<\/tr>\n \nNet cash used in financing activities from continuing operations<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n(44,985<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n(59,524<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n<\/tr>\n \nCash flows from discontinued operations:<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nNet cash provided by operating activities<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n2,362<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n45,370<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nNet cash used in investing activities<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n(9,214<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n(5,879<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n<\/tr>\n \nNet cash used in discontinued operations<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n(6,852<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n39,491<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nEffect of exchange rate changes on cash, cash equivalents and restricted cash equivalents<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n(4,890<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n5,052<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nNet increase in cash, cash equivalents and restricted cash equivalents<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n(84,850<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n(10,172<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n<\/tr>\n \nCash, cash equivalents and restricted cash equivalents at the beginning of the period<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n453,848<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n327,650<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nLess: Cash, cash equivalents and restricted cash of discontinued operations<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n(39,448<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n(35,397<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n<\/tr>\n \nCash, cash equivalents and restricted cash equivalents at the end of the period<\/p>\n<\/td>\n \n$<\/p>\n<\/td>\n \n329,550<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n$<\/p>\n<\/td>\n \n282,081<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n<\/table>\n \n\u00a0<\/p>\n View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20260507377859\/en\/<\/a><\/span><\/p>\n \nTeleflex Incorporated:\n
\n
\n
\n
\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n
\n \n \n \n \n \n \n \n \n \n \n
\n
\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n
\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n
\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n
\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n
\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n
\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n
\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n
\n \n \n \n \n \n \n \n \n \n \n \n \n
\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n
\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \u00a0<\/td>\n<\/tr>\n<\/table>\n \n
\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n <\/p>\n
\n
Lawrence Keusch
\n
Vice President, Investor Relations and Strategy Development<\/p>\n
![\"Logo\"](\"https:\/\/mms.businesswire.com\/media\/20260507377859\/en\/2710168\/3\/Teleflex_Global_Corporate_Brand_Logo_CMYK_Navy-White_%28002%29.jpg\"){kind=logo}
<\/td>\n<\/tr>\n